HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hironobu Shigaki Selected Research

Esophageal Squamous Cell Carcinoma

12/2017Fusobacterium nucleatum in gastroenterological cancer: Evaluation of measurement methods using quantitative polymerase chain reaction and a literature review.
12/2016Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
9/2016UHRF1 regulates global DNA hypomethylation and is associated with poor prognosis in esophageal squamous cell carcinoma.
6/2016The role of microRNA in esophageal squamous cell carcinoma.
12/2015Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?
11/2014Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus.
5/2014Thoracic lymph node involvement in adenocarcinoma of the esophagogastric junction and lower esophageal squamous cell carcinoma relative to the location of the proximal end of the tumor.
3/2014LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma.
12/2013KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
3/2013LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hironobu Shigaki Research Topics

Disease

16Neoplasms (Cancer)
05/2021 - 09/2009
11Esophageal Squamous Cell Carcinoma
12/2017 - 12/2012
6Carcinogenesis
09/2016 - 08/2012
5Esophageal Neoplasms (Esophageal Cancer)
12/2016 - 04/2015
5Neoplasm Metastasis (Metastasis)
12/2016 - 11/2009
4Stomach Neoplasms (Stomach Cancer)
12/2015 - 10/2013
4Genomic Instability
03/2014 - 08/2012
2Colonic Neoplasms (Colon Cancer)
12/2016 - 12/2013
2Colorectal Neoplasms (Colorectal Cancer)
02/2016 - 12/2014
2Infections
02/2016 - 04/2015
1Mental Disorders (Mental Disorder)
05/2021
1Abscess
07/2020
1Disease Progression
07/2020
1Appendicitis
07/2020
1Liver Neoplasms (Liver Cancer)
12/2017
1Pelvic Infection
12/2016
1Infarction (Infarctions)
12/2016
1Brain Infarction
12/2016
1Pelvic Neoplasms
12/2016
1Anastomotic Leak
09/2016
1Malnutrition (Nutritional Deficiencies)
08/2016
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
06/2016
1Aspergillosis
02/2016
1Intussusception
12/2015
1Intestinal Obstruction (Obstruction, Intestinal)
12/2014
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2014
1Lymphatic Diseases
11/2014
1Hypoalbuminemia
06/2014
1Adenocarcinoma
05/2014

Drug/Important Bio-Agent (IBA)

8DNA (Deoxyribonucleic Acid)IBA
12/2017 - 08/2012
5Biomarkers (Surrogate Marker)IBA
09/2016 - 12/2012
4NucleotidesIBA
09/2016 - 03/2013
2Proteins (Proteins, Gene)FDA Link
03/2016 - 12/2013
2hydrogen sulfite (bisulfite)IBA
04/2015 - 10/2013
2Indicators and Reagents (Reagents)IBA
06/2014 - 03/2014
1Anti-Bacterial Agents (Antibiotics)IBA
07/2020
1Formaldehyde (Formol)FDA Link
12/2017
1ParaffinIBA
12/2017
1AnticoagulantsIBA
12/2016
1MicroRNAs (MicroRNA)IBA
06/2016
1Messenger RNA (mRNA)IBA
03/2016
1ElementsIBA
03/2016
1C-Reactive ProteinIBA
06/2014
1DNA Transposable Elements (Element, IS)IBA
03/2014
1Codon (Codons)IBA
12/2013
1ErbB Receptors (EGF Receptor)IBA
12/2013
1GATIBA
12/2013
1Capsules (Microcapsules)IBA
09/2009

Therapy/Procedure

9Esophagectomy
12/2016 - 11/2014
5Lymph Node Excision (Lymph Node Dissection)
08/2016 - 05/2014
4Therapeutics
07/2020 - 11/2009
3Length of Stay
07/2020 - 08/2016
3Drug Therapy (Chemotherapy)
12/2016 - 12/2014
2Neoadjuvant Therapy
12/2016 - 12/2015
2Chemoradiotherapy
12/2015 - 11/2014
2Gastrectomy
12/2015 - 06/2014
1Adjuvant Chemotherapy
05/2021
1Appendectomy
07/2020
1Pelvic Exenteration
12/2016
1Aftercare (After-Treatment)
11/2014
1Molecular Targeted Therapy
12/2013